Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
ORIC Pharmaceuticals, Inc. develops clinical-stage oncology therapies designed to counter mechanisms of therapeutic resistance in cancer. News about ORIC commonly covers rinzimetostat (ORIC-944), a selective allosteric PRC2/EED inhibitor studied in prostate cancer and metastatic castration-resistant prostate cancer, and enozertinib (ORIC-114), a brain-penetrant selective inhibitor targeting EGFR exon 20 insertion mutations and EGFR atypical mutations.
Recurring updates include clinical and preclinical data presentations, development-dose decisions, oncology conference presentations, quarterly financial results, cash runway disclosures, at-the-market equity financing, and Nasdaq Rule 5635(c)(4) inducement equity grants.
ORIC (Nasdaq: ORIC) reported Phase 1b data for rinzimetostat in mCRPC and enozertinib in NSCLC, selected provisional RP2Ds, and initiated dose optimization with AR inhibitors. The company raised net proceeds totaling $264 million, reported $392.3M cash and investments (proforma $412.3M) and expects runway into 2H 2028.
ORIC plans multiple 2026 readouts and anticipates a Phase 3 registrational start for rinzimetostat in 1H 2026.
ORIC Pharmaceuticals (Nasdaq:ORIC) announced inducement equity grants made on February 2, 2026 to three new non-executive employees who joined in January 2026. ORIC granted 173,800 non-qualified stock options and 28,700 restricted stock units under its 2022 Inducement Equity Incentive Plan.
Options use the closing price on the grant date; options vest 25% after one year then monthly over 36 months, RSUs vest one-third each year for three years. Grants were approved by the Compensation Committee per Nasdaq Rule 5635(c)(4).
ORIC (Nasdaq: ORIC) announced management will participate in three investor conferences in February 2026 with fireside chats and one-on-one meetings.
Schedule: Guggenheim Emerging Outlook: Biotech Summit on Feb 12 at 10:30 a.m. ET; Citi Virtual Oncology Leadership Summit on Feb 18 at 2:30 p.m. ET; Oppenheimer Healthcare Life Sciences on Feb 25 at 12:00 p.m. ET. Webcasts and 90-day replays will be available via the company's investor website.
ORIC (NASDAQ: ORIC) reported 2025 operational highlights and 2026 milestones, emphasizing clinical progress for rinzimetostat (ORIC-944) in mCRPC and enozertinib in NSCLC. Key clinical metrics: rinzimetostat showed PSA50 in 55% (confirmed 40%), PSA90 in 20%, and ctDNA >50% reduction in 76% with 59% clearance. Enozertinib showed strong systemic activity (1L ORR 67% in EGFR exon 20; 80% in EGFR PACC) and 100% intracranial ORR in measurable CNS disease. Company selected provisional RP2Ds, plans a Phase 3 start for rinzimetostat in 1H 2026, and expects multiple 2026 readouts. Financials: raised $244M in 2025; cash and investments of $413M expected to fund operations into 2H 2028.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:45 a.m. PT.
A live webcast will be available via the company’s investor website at www.oricpharma.com, and a replay will be accessible for 90 days after the event.
ORIC (Nasdaq: ORIC) reported Phase 1b data for enozertinib (ORIC-114) in EGFR exon 20 NSCLC at ESMO Asia Congress 2025 on Dec 6, 2025. Key efficacy: 1L best ORR 67% (60% confirmed in initial cohort) and 100% intracranial confirmed ORR by BICR-RANO; 2L confirmed ORR 45% in the 80 mg cohort. Safety: mostly Grade 1–2 TRAEs, low discontinuation (2 in 1L, 3 in 2L), more dose reductions at 120 mg. Follow-up median ~30–33 weeks. Company selected 80 mg QD for potential Phase 3; enrollment continues with next update expected mid-2026. Conference call and webcast held Dec 6, 2025 at 8:00 pm ET.
ORIC Pharmaceuticals (Nasdaq:ORIC) announced inducement equity grants on December 1, 2025 to three newly hired non-executive employees who began in November 2025. The company granted 69,200 non-qualified stock options and 11,400 restricted stock units under the 2022 Inducement Equity Incentive Plan, subject to continued service through vesting dates.
The stock options use an exercise price equal to ORIC’s closing common stock price on the grant date. Options vest 25% after one year, then monthly at 1/36th of the remainder; RSUs vest one-third on each of the first three anniversaries. Grants were approved by the Compensation Committee per Nasdaq Rule 5635(c)(4) as material inducements to employment.
ORIC (NASDAQ: ORIC) reported Phase 1b data for oral enozertinib in previously treated NSCLC patients with HER2 exon 20 mutations presented at ESMO Asia Congress 2025. As of Aug 29, 2025, 49 patients were dosed (26 at 80 mg QD; 23 at 120 mg QD), with 47% having baseline brain metastases.
Key results in the 80 mg cohort: 35% ORR (26% confirmed ORR) and 100% disease control rate; manageable safety with mostly Grade 1–2 TRAEs and only 2 discontinuations. Median follow-up was 50 weeks; 32% of patients remained on treatment. Enrollment in HER2 exon 20 completed and no further development planned for that population; 80 mg QD selected for potential Phase 3 based on related cohorts.
ORIC (Nasdaq: ORIC) reported Phase 1b data for enozertinib (ORIC-114) at ESMO Asia Congress 2025 showing strong systemic and CNS activity in NSCLC with EGFR atypical and PACC mutations. In previously treated patients with PACC mutations (22 efficacy-evaluable), enozertinib achieved a 36% confirmed ORR and 91% DCR with median follow-up >32 weeks. In preliminary 1L PACC patients (10 efficacy-evaluable at 80 mg QD) the drug showed 80% ORR and 100% intracranial ORR in measurable CNS disease. Safety was manageable, with no TRAE-related discontinuations; 80 mg QD selected as the potential Phase 3 dose and next update expected mid-2026.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced two late-breaking oral presentations of Phase 1b data for enozertinib (ORIC-114) at the ESMO Asia Congress 2025 in Singapore (December 5–7, 2025).
The mini-oral (LBA15) on Dec 5, 2025 at 11:38–11:43 a.m. SGT covers previously treated EGFR atypical mutant NSCLC with randomized dose optimization and CNS activity. The proffered paper oral (LBA13) on Dec 6, 2025 at 10:02–10:12 a.m. SGT covers EGFR exon 20 mutant NSCLC in previously treated and treatment-naïve patients. ORIC will host a conference call and webcast on Dec 6, 2025 at 8:00 p.m. ET, with a replay available for 90 days.